Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: A multi-centre pilot study in China

Haemophilia

Volumn 19, Issue 1, 2013, Pages 27-34

  Tang, L ^a   Wu, R ^a   Sun, J ^b   Zhang, X ^c,c   Feng, X ^b   Luke, K H ^d   Poon, M C ^e  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b FIRST MILITARY MEDICAL UNIVERSITY   (China)

^c Hemophilia Institute of Blood Center of Shandong Province   (China)

^d CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

Children; China; Haemophilia A; Low dose prophylaxis; Secondary prophylaxis; Severe moderate

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADOLESCENT; ARTHROPATHY; ARTICLE; BLEEDING; CHILD; CHINA; DAILY LIFE ACTIVITY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEMARTHROSIS; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEDIATRICS; PILOT STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; QUESTIONNAIRE; SCHOOL CHILD; SHORT COURSE THERAPY; TREATMENT DURATION;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHINA; COAGULANTS; FACTOR VIII; FEMALE; HEMARTHROSIS; HEMOPHILIA A; HEMORRHAGE; HUMANS; MALE; PILOT PROJECTS;

EID: 84871008917     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02926.x     Document Type: Article

References (15)

1. Valentino LA. Secondary prophylaxis therapy: what are the benefits, limitations and unknowns? Haemophilia 2004; 10: 147-57.
2. Ljung R, Aronis-Vournas S, Kurnik-Auberger K et al. Treatment of children with haemophilia in Europe: a survey of 20 centers in 16 countries. Haemophilia 2000; 6: 619-24.
3. Blanchette VS, Manco-johnson M, Santagostino E et al. Optimizing factor prophylaxis for the haemophilia population: where do we stand. Haemophilia 2004; 10(Suppl. 4): 97-104.
4. Poon M-C, Luke K-H. Haemophilia care in China: achievements of a decade of World Federation of Hemophilia (WFH) Treatment Center Twinning activities. Haemophilia 2008; 14: 879-88.
5. Wu RH, Luke KH, Poon MC et al. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate hemophilia children: a pilot study in China. Haemophilia 2011; 17: 70-4.
6. World Federation of Hemophilia. Guidelines for the Management of Hemophilia, 2005. Available at http://www.wfh.org. Accessed September 22, 2010.
7. Lifecord Stat-Korea (CRO), Hwang JH. Pharmacokinetic, efficacy and safety study of GreenEight, a double (solvent/detergent + heating) virus inactivated plasma derived factor VIII concentrate, in previously treated type-A hemophilia patients. Green Cross Corporation Clinical Study Report, China, 2005.
8. Poonnoose PM, Manigandan C. Functional Independence Score in Haemophilia: a new performance-based instrument to measure disability. Haemophilia 2005; 11: 598-602.
9. Wu RH, Wu XY. Clinical material and current situation analysis in children with haemophilia. Chinese J Thromb Hemost 2008; 14: 116-20.
10. Sun SJ, Zhang L. X-ray changes and clinical analysis in 101 cases of haemophilic arthropathy. Clin Med China 2006; 22: 326-8.
11. Carcao MD, Aledort L. Prophylactic factor replacement in hemophilia (reviews). Blood 2004; 18: 101-13.
12. Manco-Johnson MJ, Nuss R, Geraghty S et al. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 1994; 47: 113-7.
13. Liesner RJ, Khair K, Hann IM. The impact of prophyactic treatment on children with severe haemophilia. Br J Haematol 1996; 92: 973-8.
14. van den Berg HM, Fischer K, van der Bom JG et al. Effects of prophylactic treatment regimens in children with severe haemophilia: a comparison of different strategies. Haemophilia 2002; 2(Suppl. 8): 43-6.
15. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.